Cronexitide lanocianine clinical trials
Also written LS301.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses cronexitide lanocianine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Integro Theranostics (3) · Samuel Achilefu (1) · Washington University School of Medicine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test cronexitide lanocianine.
Studies
Open first, then newest update. How each study uses cronexitide lanocianine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung CancerActive, not recruitingPhase 2Integro TheranosticsNCT07276789Written as LS301-IT 0.1 mg/kg
- LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast CancerCompletedPhase 1/2Integro TheranosticsNCT05900986Written as LS301-IT 0.025 mg/kg
- A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung CancerCompletedPhase 1Integro TheranosticsNCT06713564Written as LS301-IT
- Real-time Intraoperative Breast Cancer Visualization for Margin AssessmentTerminatedPhase 1/2Samuel AchilefuNCT02807597Written as LS301
- LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric SurgeryWithdrawnPhase 1/2Washington University School of MedicineNCT04105062Written as LS301
Codes
What other systems call cronexitide lanocianine · ClinicalTrials.gg INT017240
- UNII (FDA) M48HCF27ZECRONEXITIDE LANOCIANINEOne source FDA
- NCI Thesaurus C129590Cronexitide LanocianineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M48HCF27ZE | CRONEXITIDE LANOCIANINE | One source FDA |
| NCI Thesaurus | C129590 | Cronexitide Lanocianine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.